Richard Mulligan - Mar 3, 2022 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
Head of SanaX, Director
Signature
/s/ James J. MacDonald, Attorney-in-Fact for Richard Mulligan
Stock symbol
SANA
Transactions as of
Mar 3, 2022
Transactions value $
$0
Form type
4
Date filed
3/8/2022, 08:06 AM
Previous filing
Jul 2, 2021
Next filing
May 12, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Stock Options (Right to Buy) Award $0 +250K $0.00 250K Mar 3, 2022 Common Stock 250K $5.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter.